OpenAI Launches GPT-Rosalind to Transform Life Sciences Research
OpenAI has introduced GPT-Rosalind, a powerful new artificial intelligence model built to enhance biological research and accelerate innovation in the life sciences sector. The launch marks a significant step in OpenAI’s growing focus on AI-driven scientific discovery.
Named after renowned 20th-century scientist Rosalind Franklin, GPT-Rosalind is specifically designed to support complex research across biochemistry, drug discovery, and translational medicine. The model aims to streamline early-stage research processes by assisting scientists with critical tasks such as evidence synthesis, hypothesis generation, and experimental planning.
As demand for AI-powered solutions continues to rise across pharmaceutical companies, biotech firms, and academic institutions, GPT-Rosalind addresses a key need for faster and more efficient research workflows. By leveraging advanced AI capabilities, the model enables researchers to query scientific databases, analyze the latest research papers, utilize specialized tools, and even propose new experimental approaches.
According to OpenAI, GPT-Rosalind is built on its latest internal models, offering enhanced scientific reasoning and domain-specific knowledge. The company emphasized that the model is designed to support multi-step research tasks, helping scientists accelerate the discovery process from concept to experimentation.
Currently, GPT-Rosalind is available as a research preview through ChatGPT, Codex, and OpenAI’s API for qualified users under its trusted access deployment framework. In addition, OpenAI has launched a free Life Sciences research plugin for Codex, giving researchers access to more than 50 scientific tools and data sources.
OpenAI is already collaborating with leading organizations such as Amgen, Moderna, and Thermo Fisher Scientific to integrate GPT-Rosalind into real-world research workflows, further demonstrating its practical impact across the industry.
In a parallel development, OpenAI recently unveiled GPT-5.4-Cyber, a specialized version of its flagship model tailored for defensive cybersecurity applications, signaling the company’s broader push into domain-specific AI solutions.
With innovations like GPT-Rosalind, OpenAI continues to position itself at the forefront of AI-powered transformation in science, healthcare, and beyond.
